Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Philogen

- PMLiVE

BMJ accuses Boehringer of withholding Pradaxa data

Claims current FDA recommendation for anticoagulant may be flawed

- PMLiVE

Boehringer goes on PR offensive over Pradaxa report

Takes to social media to defend its position on the anticoagulant ahead of tonight's Channel 4 news report

- PMLiVE

Neuway appoints Boehringer’s Baiker to board

He has 25 years’ experience at German pharma company

- PMLiVE

Eisai’s Bose to join Boehringer

He becomes head of global marketing for oncology

- PMLiVE

The moving parts of orphan drug development

Tackling rare diseases requires high levels of cooperation, regulatory support and a determination to succeed

- PMLiVE

Amgen and Boehringer drugs win FDA breakthrough status

Leukaemia drug and Pradaxa antidote will benefit from accelerated regulatory processes

Novartis building

Novartis pulls EMA application for expanded Tasigna use

And Boehringer confirms it won't seek approval for faldaprevir as it exits hepatitis C

- PMLiVE

Biosimilar Lantus leads CHMP opinions

Boehringer and Lilly’s insulin one of six new medicines recommended for EU approval

- PMLiVE

Boehringer pulls faldaprevir and exits hepatitis C market

Unable to challenge all-oral options from Gilead and others

- PMLiVE

ADA: Empagliflozin overcomes FDA concerns

Boehringer and Lilly expect decision on diabetes treatment by end of 2014

- PMLiVE

Boehringer gets ‘kite mark’ for health information

First pharma company awarded The Information Standard Certification in UK

- PMLiVE

Pradaxa cleared for new indications in Europe

Boehringer drug set for use in deep vein thrombosis and pulmonary embolism

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links